[F]FDG PET/CT volumetric biomarkers for non-invasive prediction of HER2 expression in breast cancer patients.

Objectives: to investigate the capability of F-fluorodeoxyglucose positron emission tomography/computed tomography ([F]-FDG PET/CT) derived volumetric parameters to predict human epidermal growth factor receptor 2 (HER2) status in breast cancer patients.

Methods: retrospective study enrolled 47 female patients with breast cancer. All patients had pretreatment [F]-FDG PET/CT.

Prognostic value of initial [ 18 F]FDG PET/computed tomography volumetric and texture analysis-based parameters in patients with head and neck squamous cell carcinoma.

Aim Of Work: To determine the predictive value of initial [ 18 F]FDG PET/computed tomography (CT) volumetric and radiomics-derived analyses in patients with head and neck squamous cell carcinoma (HNSCC).

Methods: Forty-six adult patients had pathologically proven HNSCC and underwent pretherapy [ 18 F]FDG PET/CT were enrolled. Semi-quantitative PET-derived volumetric [(maximum standardized uptake value (SUVmax) and mean SUV (SUVmean), total lesion glycolysis (TLG) and metabolic tumor volume (MTV)] and radiomics analyses using LIFEx 6.

Prediction of pathological response using 18F FDG PET/CT derived metabolic parameters in locally advanced breast cancer patients.

Aim Of Work: This study aims to assess the value of flurodeoxyglucose (FDG)-PET derived metabolic parameters for prediction of pathologic response in LABC postneoadjuvant therapy.

Methods: Totally 47 patients with LABC underwent initial and postneoadjuvant therapy PET scans. ΔSUVmax%, ΔTLG% and ΔMTV% were calculated.